These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 38063316)
1. The heterogeneous impact of targeted therapy on the prognosis of stage III/IV colorectal cancer patients with different subtypes of TP53 mutations. Chen J; Chang X; Li X; Liu J; Wang N; Wu Y; Zheng L; Nie X Cancer Med; 2023 Dec; 12(24):21920-21932. PubMed ID: 38063316 [TBL] [Abstract][Full Text] [Related]
2. Pan M; Jiang C; Tse P; Achacoso N; Alexeeff S; Solorzano AV; Chung E; Hu W; Truong TG; Arora A; Sundaresan T; Suga JM; Thomas S; Habel LA J Clin Oncol; 2022 Jan; 40(2):171-179. PubMed ID: 34843402 [TBL] [Abstract][Full Text] [Related]
3. Li AJ; Li HG; Tang EJ; Wu W; Chen Y; Jiang HH; Lin MB; Yin L World J Gastroenterol; 2018 Feb; 24(5):631-640. PubMed ID: 29434452 [TBL] [Abstract][Full Text] [Related]
4. Multi gene mutation signatures in colorectal cancer patients: predict for the diagnosis, pathological classification, staging and prognosis. Zhuang Y; Wang H; Jiang D; Li Y; Feng L; Tian C; Pu M; Wang X; Zhang J; Hu Y; Liu P BMC Cancer; 2021 Apr; 21(1):380. PubMed ID: 33836681 [TBL] [Abstract][Full Text] [Related]
5. TP53 Gain-of-Function Mutation is a Poor Prognostic Factor in High-Methylated Metastatic Colorectal Cancer. Wakayama S; Ouchi K; Takahashi S; Yamada Y; Komatsu Y; Shimada K; Yamaguchi T; Shirota H; Takahashi M; Ishioka C Clin Colorectal Cancer; 2023 Sep; 22(3):327-338. PubMed ID: 37355363 [TBL] [Abstract][Full Text] [Related]
6. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie). Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682 [TBL] [Abstract][Full Text] [Related]
7. Clinical significance of frequent somatic mutations detected by high-throughput targeted sequencing in archived colorectal cancer samples. Dallol A; Buhmeida A; Al-Ahwal MS; Al-Maghrabi J; Bajouh O; Al-Khayyat S; Alam R; Abusanad A; Turki R; Elaimi A; Alhadrami HA; Abuzenadah M; Banni H; Al-Qahtani MH; Abuzenadah AM J Transl Med; 2016 May; 14(1):118. PubMed ID: 27146902 [TBL] [Abstract][Full Text] [Related]
8. Pan M; Jiang C; Zhang Z; Achacoso N; Alexeeff S; Solorzano AV; Tse P; Chung E; Sundaresan T; Suga JM; Thomas S; Habel LA JCO Precis Oncol; 2023 May; 7():e2200570. PubMed ID: 37163715 [TBL] [Abstract][Full Text] [Related]
9. TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate Cancer. Chapman L; Ledet EM; Barata PC; Cotogno P; Manogue C; Moses M; Christensen BR; Steinwald P; Ranasinghe L; Layton JL; Lewis BE; Sartor O Clin Genitourin Cancer; 2020 Apr; 18(2):148-154. PubMed ID: 31822380 [TBL] [Abstract][Full Text] [Related]
10. Fecal gene detection based on next generation sequencing for colorectal cancer diagnosis. He SY; Li YC; Wang Y; Peng HL; Zhou CL; Zhang CM; Chen SL; Yin JF; Lin M World J Gastroenterol; 2022 Jul; 28(25):2920-2936. PubMed ID: 35978873 [TBL] [Abstract][Full Text] [Related]
12. Landscape of somatic single nucleotide variants and indels in colorectal cancer and impact on survival. Zaidi SH; Harrison TA; Phipps AI; Steinfelder R; Trinh QM; Qu C; Banbury BL; Georgeson P; Grasso CS; Giannakis M; Adams JB; Alwers E; Amitay EL; Barfield RT; Berndt SI; Borozan I; Brenner H; Brezina S; Buchanan DD; Cao Y; Chan AT; Chang-Claude J; Connolly CM; Drew DA; Farris AB; Figueiredo JC; French AJ; Fuchs CS; Garraway LA; Gruber S; Guinter MA; Hamilton SR; Harlid S; Heisler LE; Hidaka A; Hopper JL; Huang WY; Huyghe JR; Jenkins MA; Krzyzanowski PM; Lemire M; Lin Y; Luo X; Mardis ER; McPherson JD; Miller JK; Moreno V; Mu XJ; Nishihara R; Papadopoulos N; Pasternack D; Quist MJ; Rafikova A; Reid EEG; Shinbrot E; Shirts BH; Stein LD; Teney CD; Timms L; Um CY; Van Guelpen B; Van Tassel M; Wang X; Wheeler DA; Yung CK; Hsu L; Ogino S; Gsur A; Newcomb PA; Gallinger S; Hoffmeister M; Campbell PT; Thibodeau SN; Sun W; Hudson TJ; Peters U Nat Commun; 2020 Jul; 11(1):3644. PubMed ID: 32686686 [TBL] [Abstract][Full Text] [Related]
13. Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer. Tomasini P; Mascaux C; Jao K; Labbe C; Kamel-Reid S; Stockley T; Hwang DM; Leighl NB; Liu G; Bradbury PA; Pintilie M; Tsao MS; Shepherd FA Clin Lung Cancer; 2019 May; 20(3):e338-e345. PubMed ID: 30770327 [TBL] [Abstract][Full Text] [Related]
14. Enhancing the landscape of colorectal cancer using targeted deep sequencing. Lee CS; Song IH; Lee A; Kang J; Lee YS; Lee IK; Song YS; Lee SH Sci Rep; 2021 Apr; 11(1):8154. PubMed ID: 33854094 [TBL] [Abstract][Full Text] [Related]
15. Clinical significance of p53 protein expression and TP53 variation status in colorectal cancer. Kim KM; Ahn AR; Park HS; Jang KY; Moon WS; Kang MJ; Ha GW; Lee MR; Chung MJ BMC Cancer; 2022 Aug; 22(1):940. PubMed ID: 36045334 [TBL] [Abstract][Full Text] [Related]
16. Clinical significance of multiple gene detection with a 22-gene panel in formalin-fixed paraffin-embedded specimens of 207 colorectal cancer patients. Gao XH; Yu GY; Hong YG; Lian W; Chouhan H; Xu Y; Liu LJ; Bai CG; Zhang W Int J Clin Oncol; 2019 Feb; 24(2):141-152. PubMed ID: 30612269 [TBL] [Abstract][Full Text] [Related]
17. Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11. La Fleur L; Falk-Sörqvist E; Smeds P; Berglund A; Sundström M; Mattsson JS; Brandén E; Koyi H; Isaksson J; Brunnström H; Nilsson M; Micke P; Moens L; Botling J Lung Cancer; 2019 Apr; 130():50-58. PubMed ID: 30885352 [TBL] [Abstract][Full Text] [Related]
18. Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations. Mouradov D; Domingo E; Gibbs P; Jorissen RN; Li S; Soo PY; Lipton L; Desai J; Danielsen HE; Oukrif D; Novelli M; Yau C; Holmes CC; Jones IT; McLaughlin S; Molloy P; Hawkins NJ; Ward R; Midgely R; Kerr D; Tomlinson IP; Sieber OM Am J Gastroenterol; 2013 Nov; 108(11):1785-93. PubMed ID: 24042191 [TBL] [Abstract][Full Text] [Related]
19. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis. Qin K; Hou H; Liang Y; Zhang X BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384 [TBL] [Abstract][Full Text] [Related]
20. Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies. Russo A; Bazan V; Agnese V; Rodolico V; Gebbia N Ann Oncol; 2005 May; 16 Suppl 4():iv44-49. PubMed ID: 15923428 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]